Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC

Melbourne (Australia) – 16 Mar 2020. Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer drugs

Telix Pharmaceuticals Limited is pleased to announce it is a co-recipient of a $500,000 research grant from the Government-funded Innovative Manufacturing Cooperative Research Centre (IMCRC) to fund R&D aimed at advancing Australian manufacturing capabilities for molecularly-targeted radiation (MTR) drugs for prostate, kidney and neuroendocrine cancers.

The research grant has been awarded to a group of Melbourne, Victoria-based organisations brought together by the IMCRC, comprising Telix, Cyclotek, GenesisCare, iPHASE Technologies and the School of Chemistry, Bio21 Institute, University of Melbourne.

To read the full media release please click here.